LONDON (ICIS)--Evonik is investing in a short-term expansion of its specialty lipids production at its Hanau and Dossenheim sites as part of its partnership with Pfizer-BioNTech, the German specialty chemicals producer said on Thursday.
Commercial quantities of lipids are set for production from these sites as early as the second half of 2021, which will be used in the production of coronavirus mRNA vaccines.
The mRNA is enclosed in a lipid nanoparticle (LNP) and delivered into the cell, where it is released and can then take effect.
Evonik has been involved in various mRNA-based vaccine projects for Covid-19, including the production of the specific lipids required to deliver the vaccine into cells.
The specialty producer has been involved in LNP production since 2016 when it acquired Transferra Nanosciences in Burnaby, Canada.
It then expanded its portfolio with the acquisition of US-based Wilshire Technologies in 2020.